Search results
Showing 1501 to 1550 of 1596 results for nice quality standards or clinical guidelines
Social anxiety disorder: recognition, assessment and treatment (CG159)
This guideline covers recognising, assessing and treating social anxiety disorder (also known as ‘social phobia’) in children and young people (from school age to 17 years) and adults (aged 18 years and older). It aims to improve symptoms, educational, occupational and social functioning, and quality of life in people with social anxiety disorder.
Good practice guidance – Integrated process statement (PMG12)
Good practice guidance – Integrated process statement
Occipital nerve stimulation for intractable chronic migraine (IPG452)
Evidence-based recommendations on occipital nerve stimulation for intractable chronic migraine. This involves using implanted electrodes to deliver electrical impulses to the occipital nerve to mask migraine pain.
View recommendations for IPG452Show all sections
Sections for IPG452
Guide to the methods of technology appraisal 2013
This quality standard covers the health and wellbeing of looked-after children and young people (from birth to 18 years) and care leavers (including young people planning to leave care or under leaving care provisions). It is for all settings and services that work with and care for looked-after children and young people, wherever they are living (for example, with family or friends, with foster families or in residential care). It describes high-quality care in priority areas for improvement.
View quality statements for QS31Show all sections
Sections for QS31
- Quality statements
- Quality statement 1: Warm, nurturing care
- Quality statement 2: Collaborative working between services and professionals
- Quality statement 3: Stability and quality of placements
- Quality statement 4: Support to explore and make sense of identity and relationships
- Quality statement 5: Support from specialist and dedicated services
- Quality statement 6: Continuity of services for placements outside the local authority or health boundary
- Quality statement 7: Support to fulfil potential
Percutaneous electrical nerve stimulation for refractory neuropathic pain (IPG450)
Evidence-based recommendations on percutaneous electrical nerve stimulation for refractory neuropathic pain. This involves inserting electrode needles underneath the skin connected to a stimulator device.
View recommendations for IPG450Show all sections
Sections for IPG450
Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.
Antisocial personality disorder: prevention and management (CG77)
This guideline covers principles for working with people with antisocial personality disorder, including dealing with crises (crisis resolution). It aims to help people with antisocial personality disorder manage feelings of anger, distress, anxiety and depression, and to reduce offending and antisocial behaviour.
Recent research has found that that the number of children being treated with epilepsy has fallen dramatically in the last decade.
Hepatitis B and C testing: people at risk of infection (PH43)
This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making
How NICE can help Clinical Commissioning Groups deliver high quality care
Find out about the range of NICE products that can help Clinical Commissioning Groups deliver high quality care.
Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)
Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.
This quality standard covers care for adults (aged 18 and over) who are malnourished or at risk of malnutrition in hospital or in the community. It includes identifying people at risk of malnutrition and providing nutrition support, including dietary changes and artificial nutrition support given through feeding tubes (enteral nutrition) or directly into a vein (parenteral nutrition). It describes high-quality care in priority areas for improvement.
View quality statements for QS24Show all sections
Sections for QS24
- Introduction and overview
- List of quality statements
- Quality statement 1: Screening for the risk of malnutrition
- Quality statement 2: Treatment
- Quality statement 3: Documentation and communication of results and nutrition support goals
- Quality statement 4: Self-management of artificial nutrition support
- Quality statement 5: Review
- Using the quality standard
This guideline covers encouraging people to increase the amount they walk or cycle for travel or recreation purposes.
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis (CF)
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
Laparoscopic gastric plication for the treatment of severe obesity (IPG432)
Evidence-based recommendations on laparoscopic gastric plication for the treatment of morbid obesity. This involves folding the stomach in on itself and stitching it together to reduce its volume.
View recommendations for IPG432Show all sections
Sections for IPG432
This quality standard covers assessment and treatment of drug use disorders in adults (aged 18 and over). It includes treating the misuse of opioids, cannabis, stimulants and other drugs in all settings, including inpatient and specialist residential and community-based treatment settings, and prison services. It describes high-quality care in priority areas for improvement.
View quality statements for QS23Show all sections
Sections for QS23
- Quality statements
- Quality statement 1: Needle and syringe programmes
- Quality statement 2: Assessment
- Quality statement 3: Families and carers
- Quality statement 4: Blood-borne viruses
- Quality statement 5: Information and advice
- Quality statement 6: Keyworking – psychosocial interventions
- Quality statement 7: Recovery and reintegration
This guideline covers supporting the social and emotional wellbeing of vulnerable children under 5 through home visiting, childcare and early education. It aims to optimise care for young children who need extra support because they have or are at risk of social or emotional problems.
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Decisions around whether to offer a person surgical treatment should not be based on age and fitness, according to a new report.
The NICE public health guidance development process (third edition) (PMG5)
The NICE public health guidance development process (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection
- 3 The guidance development processes
- 4 The role of stakeholders in the guidance development process
- 5 The role of the Public Health Advisory Committees (PHACs) in the development of public health guidance
- 6 The role of evidence providers
- 7 The role of the CPHE project team
- 8 Fieldwork
Methods for the development of NICE public health guidance (third edition) (PMG4)
Methods for the development of NICE public health guidance (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection and scoping the guidance
- 3 Determining the evidence for review and consideration
- 4 Identifying the evidence
- 5 Reviewing the scientific evidence
- 6 Incorporating health economics
- 7 Developing recommendations
- Appendix A Conceptual framework for the work of the Centre for Public Health Excellence (CPHE)
Neutropenic sepsis: prevention and management in people with cancer (CG151)
This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care. It aims to reduce the risk of infection in people with neutropenia (low number of white blood cells) who are receiving anticancer treatment and improve management of neutropenic sepsis.
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)
Evidence summaries: unlicensed and off-label medicines – Interim process statement
Good practice guidance – Interim process statement
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis and preventing a pulmonary embolism or another deep vein thrombosis in adults.
Patients with blood clots should be treated within 4 hours, says NICE
People who present to hospital with blood clots in the legs or lungs should be offered treatment within 4 hours and have their investigative tests including scans within 24 hours, according to latest guidelines.
Meningitis (bacterial) and meningococcal septicaemia in children and young people (QS19)
March 2024: We have temporarily withdrawn this quality standard due to the update to the NICE guideline on meningitis, which underpins the quality statements.
See the quality standard in development page. for progress on this update.
Evidence summaries: new medicines – Interim process statement (PMG1)
Evidence summaries: new medicines – Interim process statement
This quality standard covers the recognition and initial management of ovarian cancer. It describes high-quality care in priority areas for improvement.
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular oedema in adults.
Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after total hip or knee replacement in adults.
Breast reconstruction using lipomodelling after breast cancer treatment (IPG417)
Evidence-based recommendations on breast reconstruction using lipomodelling after breast cancer treatment. This involves taking fat from the abdomen or thighs and injecting it into the breast in the area of the deformity caused by surgery.
View recommendations for IPG417Show all sections
Sections for IPG417
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)
Evidence-based recommendations on fulvestrant (Faslodex), for treating locally advanced or metastatic breast cancer in adults.
This guideline covers the components of a good experience of service use. It aims to make sure that all adults using NHS mental health services have the best possible experience of care.
Healthcare-associated infections: prevention and control (PH36)
This quality improvement guide was produced by NICE, in partnership with Public Health England (PHE). Its aim is twofold: to reduce the risk of harm from healthcare-associated infections for patients, staff and visitors; and to reduce the costs associated with preventable infection.
Show all sections
Sections for PH36
- Overview
- Introduction
- Quality improvement statement 1: Board-level leadership to prevent HCAIs
- Quality improvement statement 2: Be a learning organisation
- Quality improvement statement 3: HCAI surveillance
- Quality improvement statement 4: Workforce capacity and capability
- Quality improvement statement 5: Environmental cleanliness
- Quality improvement statement 6: Multi-agency working to reduce HCAIs
Ticagrelor for the treatment of acute coronary syndromes (TA236)
Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.
Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
Type 2 diabetes prevention: population and community-level interventions (PH35)
This guideline covers preventing type 2 diabetes in adult populations and communities who are at high risk. It aims to promote a healthy diet and physical activity at community and population level, and recommends how to tailor services for people in ethnic communities and other groups who are particularly at risk of type 2 diabetes.
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.
Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.
Unintentional injuries: prevention strategies for under 15s (PH29)
This guideline covers strategies, regulation, enforcement, surveillance and workforce development in relation to preventing unintentional injuries in the home, on the road and during outdoor play and leisure.
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
Unintentional injuries in the home: interventions for under 15s (PH30)
This guideline covers home safety assessments, supplying and installing safety equipment and providing education and advice. It aims to prevent unintentional injuries among all children and young people aged under 15 but, in particular, those living in disadvantaged circumstances.
View recommendations for PH30Show all sections
Sections for PH30
- Overview
- 1 Recommendations
- 2 Public health need and practice
- 3 Considerations
- 4 Recommendations for research
- 5 References
- Appendix A: Membership of the Public Health Interventions Advisory Committee (PHIAC), the NICE project team and external contractors
- Appendix B: Summary of the methods used to develop this guidance
Unintentional injuries on the road: interventions for under 15s (PH31)
This guideline covers road speed limits, 20 mph zones and engineering measures to reduce speed or make routes safer.
View recommendations for PH31Show all sections
Sections for PH31
- Introduction
- 1 Recommendations
- 2 Public health need and practice
- 3 Considerations
- 4 Recommendations for research
- 5 References
- Appendix A: Membership of the Public Health Interventions Advisory Committee (PHIAC), the NICE project team and external contractors
- Appendix B: Summary of the methods used to develop this guidance